Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Help Wanted: FDA Begins Search for New CDER Director

This article was originally published in RPM Report

Executive Summary

FDA has a lot of hard work ahead to make the new drug safety law a reality. Its first task: find a new director for the Center for Drug Evaluation & Research. That decision might be the most important one the agency makes in determining how the new law works.

Related Content

Translating Obama For FDA
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
FDA Insider: Agency Looks Carefully Inside for New CDER Head
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
FDA Amendments Act: More Regulation = More Comfort and More Products
Avandia and the Commercial Impact of FDA's Credibility Gap
The Politics of Drug Safety: An FDA Whistleblower's Push for Reform
FDA's Selective Response to the IoM Drug Safety Report
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts